Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 197 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Hyperplasia Clear all
Terminated Phase 2 Interventional

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

NCT00116571
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
Drug · Device
Lead sponsor
QLT Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
San Bernardino, California • Shreveport, Louisiana • Greenbelt, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2006 · Synced Sep 11, 2026, 3:27 PM EDT
Terminated Phase 2 Interventional

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00237536
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Lonidamine
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
65 Years to 80 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
34
States / cities
Tucson, Arizona • Atherton, California • Culver City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 11, 2026, 3:27 PM EDT
Completed No phase listed Observational

Prostate Mechanical Imager (PMI) Clinical Bridging Study

NCT00822952
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Artann Laboratories
Industry
Eligibility
21 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Minneapolis, Minnesota • Rochester, Minnesota • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 11, 2026, 3:27 PM EDT
Recruiting Phase 2 Interventional

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 11, 2026, 3:27 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

NCT05148156
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Urolift
Device
Lead sponsor
Northwell Health
Other
Eligibility
50 Years to 99 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Syosset, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 11, 2026, 3:27 PM EDT
Terminated Phase 3 Interventional Results available

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00449150
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
46
States / cities
Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 11, 2026, 3:27 PM EDT
Recruiting No phase listed Observational

Effect of Group Preoperative Pelvic Floor Training for HoLEP

NCT05719220
View directory record Official record
Conditions
BPH, Urinary Incontinence
Interventions
Group preoperative pelvic floor training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 90 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 11, 2026, 3:27 PM EDT
Active, not recruiting No phase listed Observational

OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

NCT06560476
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Data collection
Other
Lead sponsor
Urotronic Inc.
Industry
Eligibility
Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Tampa, Florida • Kearney, Nebraska • Omaha, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Phase 1Phase 2 Interventional

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

NCT01454349
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Laguna Hills, California • Long Beach, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 11, 2026, 3:27 PM EDT
Recruiting Phase 2 Interventional

Effects of TNF Blockade on Human BPH/LUTS

NCT06062875
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Adalimumab
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 11, 2026, 3:27 PM EDT
Not listed Phase 1 Interventional

Study of the Effects of Pomegranate Tablets on Enlarged Prostates

NCT00381108
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo Tablet, Pomegranate Tablet
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

NCT00947882
View directory record Official record
Conditions
Lower Urinary Tract Symptoms (LUTS)
Interventions
Placebo, Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Homewood, Alabama • Mobile, Alabama • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

A Study in Benign Prostatic Hyperplasia

NCT01152190
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Garden City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Not applicable Interventional Results available

Pivotal Study to Assess the Safety and Effectiveness of the iTind Device

NCT02506465
View directory record Official record
Conditions
Benign Prostate Hyperplasia
Interventions
iTIND, Sham Arm
Device · Procedure
Lead sponsor
Medi-Tate Ltd.
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Pompano Beach, Florida • Baltimore, Maryland • Brooklyn, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 11, 2026, 3:27 PM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

NCT06312722
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Optilume® BPH Catheter System
Device
Lead sponsor
Urotronic Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Little Rock, Arkansas • Tampa, Florida • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Not applicable Interventional

Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices

NCT02015806
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy
Interventions
RxTimerCap, Take-N-Slide, Pillbox
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
53,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Woonsocket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 11, 2026, 3:27 PM EDT
Terminated Not applicable Interventional

Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)

NCT01896973
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Vortx Rx - Histotripsy BPH Device
Device
Lead sponsor
HistoSonics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 11, 2026, 3:27 PM EDT
Active, not recruiting Not applicable Interventional

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

NCT06051942
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Localized Prostate Cancer
Interventions
Robotic Waterjet Treatment
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
Up to 80 Years · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
La Mesa, California • Glenview, Illinois • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

NCT00848081
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
28
States / cities
Huntsville, Alabama • Anchorage, Alaska • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 11, 2026, 3:27 PM EDT
Recruiting No phase listed Observational

BPH Global Registry

NCT05543200
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Not listed
Lead sponsor
Société Internationale d'Urologie
Other
Eligibility
18 Years and older · Male only
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Phase 3 Interventional

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

NCT01966614
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug · Other
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years and older · Male only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 11, 2026, 3:27 PM EDT
Terminated No phase listed Observational

IIT-2022-Simultaneous Urolift™ and Median Lobe Enucleation

NCT06157164
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 11, 2026, 3:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)

NCT03131544
View directory record Official record
Conditions
BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
Interventions
MRI Guided Transrectal Periuretheral Transitional Zone Ablation
Device
Lead sponsor
Prostate Laser Center, PLLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 11, 2026, 3:27 PM EDT